Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360)

Clin Infect Dis. 2003 Aug 15;37(4):567-78. doi: 10.1086/375843. Epub 2003 Jul 29.

Abstract

We undertook a prospective study to analyze cytomegalovirus (CMV) end-organ disease (EOD) in subjects with advanced human immunodeficiency virus (HIV) infection. Of 403 individuals without prior CMV EOD who were followed up for a median of 151 weeks, 56 died and 21 developed CMV EOD. Twenty of the subjects with CMV EOD had CD4 cell counts of < or =50 cells/mm3 and HIV RNA level of >10,000 copies/mL of plasma at baseline; in these 20 subjects, an increase of CMV DNA level to greater than the quantification limits was associated with CMV EOD. A CD4 cell count of < or =100 cells/mm3 and an HIV RNA level of >10,000 copies/mL of plasma at baseline, a CMV DNA level of >200 copies/mL of blood during follow-up, or development of CMV EOD were all associated with decreased survival. HIV-infected subjects with CD4 cell counts of < or =50 cells/mm3 and HIV RNA levels of >10,000 copies/mL of plasma should have blood fractions screened for CMV DNA; if CMV DNA is detected, CMV prophylaxis might be considered.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / immunology
  • AIDS-Related Opportunistic Infections / mortality
  • AIDS-Related Opportunistic Infections / prevention & control*
  • Adult
  • Antiviral Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Cytomegalovirus / genetics
  • Cytomegalovirus / physiology*
  • Cytomegalovirus Infections / immunology
  • Cytomegalovirus Infections / prevention & control*
  • DNA, Viral / blood
  • Female
  • Follow-Up Studies
  • HIV / drug effects
  • HIV / genetics
  • HIV / physiology*
  • HIV Infections / complications
  • HIV Infections / immunology
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • RNA, Viral / blood
  • Survival Rate
  • Viral Load*

Substances

  • Antiviral Agents
  • DNA, Viral
  • RNA, Viral